PCSK9 Inhibitors and Their Long-Term Side Effects

PCSK9 inhibitors have been used widely enough and studied long enough that their safety profile is reassuringly clean. Across trials lasting up to five years, and now with growing real-world registry data, these drugs have not produced the kinds of serious organ damage or accumulating toxicity that some clinicians initially worried about when LDL cholesterol began dropping to levels rarely seen in nature. The concerns that persisted longest, particularly around brain function and diabetes risk, have largely been addressed by dedicated studies, though a few open questions remain.

How These Drugs Work, Briefly

PCSK9 is a protein your liver makes. It latches onto LDL receptors on liver cells and escorts them to a disposal pathway, reducing the number of receptors available to pull LDL cholesterol out of your blood. The approved monoclonal antibody drugs, evolocumab and alirocumab, block PCSK9 from grabbing those receptors. With more receptors staying active on the liver cell surface, the liver clears more LDL from the bloodstream, and cholesterol levels drop substantially.

The Five-Year Safety Record

The longest-running trial of a PCSK9 inhibitor monoclonal antibody, OSLER-1, followed patients on evolocumab for up to five years. Yearly rates of serious side effects ranged from about 7% to 8%, which matched the rate seen in patients taking standard treatment alone. Roughly 6% of patients stopped the drug because of side effects over the full study period. No one developed neutralizing antibodies against the drug, the kind that would render it ineffective or cause immune reactions.

On the efficacy side, the FOURIER open-label extension, which added a median of five more years of follow-up, showed that cardiovascular benefits tended to grow over time rather than fade. Patients with disease in multiple coronary arteries saw risk reductions for major cardiovascular events approaching 37% to 38% over the extended period.

This matters because one of the early anxieties about these drugs was whether driving LDL very low for years on end might produce some slow-burning harm. The accumulating data suggest it does not, while the cardiovascular protection continues to accrue.

The Neurocognitive Question

When PCSK9 inhibitors first arrived, the single biggest patient concern was memory. Cholesterol is a structural component of brain cells, and very low blood levels of LDL raised the theoretical possibility that the brain might be deprived. This worry was amplified by scattered reports in early trials of patients mentioning cognitive symptoms. The issue has now been investigated from several angles, and the verdict is consistently reassuring.

A systematic review and meta-analysis pooling data from multiple randomized trials found no difference in neurocognitive side effects between patients on PCSK9 inhibitors and those on placebo. The pooled risk ratio was essentially 1.0. Interestingly, a meta-regression of the evolocumab data found that longer study duration was actually associated with a slightly decreased risk of neurocognitive events, the opposite of what you would expect if the drugs were slowly damaging the brain.

⁴

A real-world observational study tracked cognitive performance in 158 patients on either evolocumab or alirocumab for about two years, using a standard screening tool. Overall cognitive scores did not change. Across individual domains like attention, language, and spatial reasoning, nothing moved. The one domain that did shift was delayed recall memory, which slightly improved. Critically, patients whose LDL dropped below 55 mg/dL scored no differently from those whose LDL stayed higher.

⁵

A 2025 study combining real-world adverse event reports with genetic analysis also found no link between PCSK9 inhibitors and memory loss, reinforcing the picture from clinical trials.

⁶

The reason the brain appears unaffected is probably that neurons make their own cholesterol locally. They do not rely on LDL particles delivered from the bloodstream. The blood-brain barrier largely prevents circulating LDL from getting in anyway. So even when blood LDL drops to very low levels, the brain’s cholesterol supply continues as normal.

Diabetes and Blood Sugar

Statins, the most widely prescribed cholesterol drugs, carry a modest but real risk of tipping people into diabetes. Because PCSK9 inhibitors lower LDL through a partially overlapping pathway, researchers expected they might do the same. The picture here is more nuanced than with cognition.

In the large cardiovascular outcome trials FOURIER and ODYSSEY, the rate of new diabetes diagnoses was not significantly higher in patients on PCSK9 inhibitors compared to placebo. But Mendelian randomization studies, which use natural genetic variation in PCSK9 as a proxy for lifelong drug exposure, have mostly pointed toward a modestly increased diabetes risk. Post-marketing safety reports have noted that evolocumab and alirocumab were primarily linked to mild blood sugar elevations rather than outright diabetes, with most episodes occurring within the first six months of treatment.

⁷

A clinical study tracking new diabetes cases found that all new diagnoses in patients on PCSK9 inhibitors occurred among people who already had prediabetes at the start. The rate of new diabetes was about 5% per year in those with prediabetes, which was statistically indistinguishable from the rate in matched control groups not taking the drugs. Baseline fasting glucose was the only factor independently associated with developing diabetes. Among people who already had diabetes, blood sugar and hemoglobin A1c levels did not worsen.

⁸

The practical takeaway: if you are starting a PCSK9 inhibitor and your fasting blood sugar is already borderline, your doctor should monitor it. But the drugs do not appear to create diabetes risk where none existed before.

Stroke Risk and Hemorrhagic Bleeding

High-dose statins have been associated with a small increase in hemorrhagic stroke, the kind caused by bleeding in the brain rather than a clot. Because PCSK9 inhibitors push LDL even lower than statins can, this was a logical concern. The data, however, show a striking divergence between the two drug classes.

A comparative meta-analysis found that statins were associated with about a 15% increase in hemorrhagic stroke risk, rising to a 53% increase at higher doses. PCSK9 inhibitors showed no increase at all. In patients with a prior ischemic stroke, statins magnified hemorrhagic stroke risk, while PCSK9 inhibitors did not.

⁹

Meanwhile, a separate meta-analysis showed that PCSK9 inhibitors reduced the risk of ischemic stroke by about 24% and total stroke by about 23% compared to controls, with no uptick in hemorrhagic events.

¹⁰

Why statins and PCSK9 inhibitors diverge on hemorrhagic stroke despite both lowering LDL is not fully understood. Statins have pleiotropic effects beyond cholesterol, including actions on blood vessel walls and platelet function, which may contribute to their hemorrhagic stroke signal. PCSK9 inhibitors work through a more targeted mechanism.

Hormones and Vitamins at Very Low LDL Levels

LDL particles carry more than just cholesterol. They also transport fat-soluble vitamins like vitamin E and serve as a precursor pool for steroid hormones like cortisol, estrogen, and testosterone. Driving LDL very low could theoretically starve the body of these molecules.

The DESCARTES trial specifically tracked vitamin E levels, cortisol, and gonadal hormones in patients on evolocumab over a year. Cortisol rose slightly, but the ratio of cortisol to its controlling hormone did not change, suggesting the adrenal glands were functioning normally. Sex hormones did not change. These findings held even in patients whose LDL dropped below about 15 mg/dL, a level that would have been considered impossibly low a generation ago.

¹¹

Cataracts and Eye Health

Another concern tied to extremely low LDL was the possibility of cataracts. The lens of the eye depends on cholesterol for its structure, and animal studies decades ago had raised alarms. A meta-analysis covering more than 83,000 patients across five PCSK9 inhibitor trials found essentially identical cataract rates in the drug and placebo groups, and no relationship between how low LDL dropped and how many cataracts developed.

¹²

Kidney and Liver Tolerability

Patients with chronic kidney disease are at high cardiovascular risk and often need aggressive cholesterol lowering, so knowing how PCSK9 inhibitors interact with impaired kidneys matters. A study of patients across different stages of kidney function found that creatinine levels and estimated kidney filtration rates stayed stable during treatment, and the rate of side effects did not differ by kidney function group.

¹³

Liver enzymes have not been a consistent concern in the monoclonal antibody trials. Unlike statins, which are metabolized by the liver and occasionally provoke enzyme elevations, PCSK9 inhibitors are proteins that are broken down by the body’s normal antibody-clearing pathways rather than through liver metabolism.

Injection Site Reactions and Immunogenicity

Because evolocumab and alirocumab are injected under the skin every two to four weeks, local reactions are the most common nuisance side effect. These are typically mild: redness, itching, or swelling at the injection site that resolves without treatment. An interesting case series documented patients who had tolerated alirocumab for months without issue, then suddenly developed injection site reactions after an unrelated immune activation event, such as a respiratory infection or a COVID-19 vaccination. Once the immune stimulation resolved, the reactions disappeared and did not return.

¹⁴

Anti-drug antibodies, where the immune system starts targeting the drug itself, have been a non-issue for the approved PCSK9 monoclonal antibodies. In the five-year OSLER-1 trial, a handful of patients developed transient binding antibodies, but no one developed the neutralizing kind that would blunt the drug’s effect.

This stands in sharp contrast to bococizumab, a PCSK9 inhibitor that never made it to market. In clinical trials, about 44% of patients on bococizumab developed anti-drug antibodies, and 27% developed neutralizing ones. The drug’s cholesterol-lowering effect faded substantially in those patients. The key difference is that evolocumab and alirocumab are fully human antibodies, while bococizumab was a humanized mouse antibody, retaining enough non-human sequences for the immune system to flag it as foreign.

¹⁵ Cross-reactivity testing showed that antibodies against bococizumab did not meaningfully react with evolocumab or alirocumab, confirming the drugs are immunologically distinct.

What Genetic Evidence Tells Us About Lifelong Low PCSK9

Some people are born with loss-of-function variants in the PCSK9 gene, meaning their bodies make less of the protein or a less effective version of it. These individuals have lived with naturally lower LDL for their entire lives, essentially serving as human experiments in what decades of PCSK9 inhibition might look like. A large genetic study examined whether these people showed any heart structural abnormalities or increased heart failure risk. They did not. Carriers of PCSK9 loss-of-function variants had normal heart chamber sizes, normal ejection fractions, and no increased odds of heart failure.

¹⁶

This genetic evidence is particularly valuable because it speaks to truly lifelong exposure, something no clinical trial can replicate. If having low PCSK9 activity from birth does not produce organ damage or structural heart disease, it provides strong reassurance that inhibiting the protein with a drug for years or decades is unlikely to cause hidden harm.

Real-World Adherence and Why People Stop

Clinical trials select motivated patients and monitor them closely, so real-world data matters for understanding what happens outside that controlled environment. A prospective registry study found that side effects occurred in about 31% of patients, though major cardiovascular events were infrequent. The overall conclusion was that the drugs are safe in routine practice.

¹⁷

Persistence, meaning whether patients are still taking the drug over time, is a different story. In one specialty pharmacy model, about 80% of patients were still on treatment at one year, dropping to 68% at two years. Among those who stopped, side effects were the most commonly cited reason, accounting for over half of discontinuations. The second most common reason was simply losing contact with the healthcare system.

¹⁸

In a separate study from Singapore, high medication cost was the leading reason for stopping. About a third of patients had inadequate adherence, often because of the financial burden of the drugs rather than tolerability problems.

¹⁹

The gap between “safe in a trial” and “people actually keep taking it” is worth noting. Many discontinuations are driven by cost, logistics, or the inconvenience of injections rather than by any dangerous side effect.

Inclisiran and the Next Generation

Inclisiran works on the same target, PCSK9, but through a fundamentally different mechanism. Instead of blocking the protein after it is made, inclisiran is a small interfering RNA molecule that prevents liver cells from producing PCSK9 in the first place. It requires only two injections per year after the initial loading doses, which dramatically reduces the adherence burden.

A pooled safety analysis covering more than 3,500 patients treated with inclisiran for up to six years found no new safety signals. Rates of serious side effects, liver and kidney events, muscle problems, and new diabetes were comparable between inclisiran and placebo. Anti-drug antibodies developed in fewer than 5% of patients, and persistent antibodies were rare. No one developed the kind of immune activation or nerve damage that had been a theoretical concern with RNA-based therapies.

²⁰

In the four-year ORION-3 extension study, injection site reactions occurred in about 14% of patients, and treatment-related serious side effects were reported in just 1%. Twice-yearly dosing maintained steady LDL reductions throughout the study period.

²¹

The most common side effects with inclisiran have been injection site reactions, musculoskeletal pain, headache, and upper respiratory symptoms, all occurring at rates similar to placebo. Across the published ORION trials, no patient stopped therapy because of side effects.

²²

Beyond inclisiran, an oral PCSK9 inhibitor called enlicitide has entered clinical trials. In a randomized study of adults with familial hypercholesterolemia, enlicitide was well tolerated, with side effect rates comparable to placebo. If oral PCSK9 inhibitors prove durable in larger trials, they could eliminate the injection barrier entirely.

²³

PCSK9 Inhibition and the Immune System

PCSK9 does more than regulate cholesterol. It also affects how the body handles bacterial toxins during severe infections. In sepsis, PCSK9 degrades the receptors that liver and fat cells use to clear dangerous lipids shed by bacteria. Animal studies have shown that knocking out PCSK9 or inhibiting it with drugs improved survival in severe infections by boosting the clearance of bacterial toxins and dampening the inflammatory response.

²⁴

In humans, people carrying natural PCSK9 loss-of-function variants showed improved survival in septic shock and reduced inflammatory cytokine levels. In the ODYSSEY OUTCOMES trial, deaths from sepsis were numerically lower in the alirocumab group than in the placebo group, though the numbers were too small to reach statistical significance.

²⁵

This is still early-stage research, but it raises the intriguing possibility that PCSK9 inhibitors may have benefits beyond cholesterol, potentially improving the body’s ability to fight certain severe infections. No trial has been designed to test this as a primary endpoint in humans yet, so this remains a hypothesis rather than a clinical recommendation.

Use in Children and Older Adults

Children with familial hypercholesterolemia face a lifetime of dangerously elevated cholesterol and can develop heart disease by their twenties. A systematic review and meta-analysis of randomized trials in children and adolescents found no evidence of differences between PCSK9 inhibitors and placebo in tolerability, growth, maturation, or overall side effects. The caveat is that the available pediatric trials are few in number and short in duration, so long-term safety in growing bodies remains an open question.

²⁶

At the other end of the age spectrum, older adults are the population most likely to need aggressive LDL lowering. A retrospective review found that side effects led to drug discontinuation in a meaningful fraction of elderly patients, though the study was small. Age-related polypharmacy and frailty may increase sensitivity to injection site reactions and musculoskeletal complaints, even when the drug itself is not causing organ-level harm.

²⁷